Full Press Release Details
EIP Pharma Closes $11.2 Million Financing Round to Advance Development of Neflamapimod in Additional Neurodegenerative Disease Indications.
CRVO
EIP Pharma Closes $11.2 Million Financing Round to Advance Development of Neflamapimod in Additional Neurodegenerative Disease Indications
Key Takeaway: EIP Pharma Closes $11.2 Million Financing Round to Advance Development of Neflamapimod in Additional Neurodegenerative Disease Indications